The Australian company is now looking for partners with a positive interim analysis of data from the ACTION3 Phase 3 trial of DMX-200 in patients with a debilitating kidney disease. …
Dimerix's DMX-200 successfully passes interim analysis in ACTION3 Phase 3 trial
March 11, 2024 Australian Biotech
Latest Video
New Stories
-
Sanofi treatment for ultra-rare ASMD to be made available through LSDP
October 22, 2025 - - Latest News -
Sigma reports strong growth and upgraded synergies in first full year post-merger
October 22, 2025 - - Latest News -
IDT Australia sharpens strategy with cost savings and radiopharmaceutical focus
October 21, 2025 - - Latest News -
FOI reforms set back transparency decades and will impact public health decision-making
October 21, 2025 - - Latest News -
Astellas' XTANDI achieves landmark survival milestone in prostate cancer
October 21, 2025 - - Latest News -
Services Australia reports record number of processed PBS prescriptions
October 21, 2025 - - Latest News -
Endometriosis diagnoses in Australian GP clinics nearly double over a decade
October 21, 2025 - - Latest News